Correlation Analysis Between Peripheral Blood PrPC Levels and Disease Severity and Prognosis in Patients With Acute Cerebral Infarction

March 31, 2026 updated by: The First Hospital of Jilin University
The primary objective of this observational study is to investigate alterations in PrPc levels in peripheral blood during acute cerebral infarction, as well as the correlation between these changes and both disease severity and prognosis. Additionally, it aims to explore the association between peripheral blood PrPc and T-cell-mediated inflammatory responses in acute cerebral infarction. Key research questions addressed include: how PrPc concentrations in peripheral blood change during acute cerebral infarction, and whether such variations correlate with clinical severity and patient outcomes. No interventions were administered in this study, and all patients received standard diagnostic and therapeutic care without disruption. Fasting venous blood samples were collected on the morning following hospital admission, and follow-up assessments using the modified Rankin Scale (mRS) were conducted at 90 days post-onset.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

79

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Jilin
      • Changchun, Jilin, China, 130021
        • The First Hospital of Jilin University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

patients with anterior circulation ischemic stroke who were admitted to the Department of Neurology of the First Hospital of Jilin University within 48 hours of symptom onset and were aged 18-80 years were consecutively enrolled in this study. For wake-up strokes, onset was defined as last known well. Anterior circulation ischemic stroke patients were defined by infarct location within the ICA-MCA and/or ACA territories on MRI-DWI (supported by CTA/MRA when available).

Description

Inclusion Criteria:

  • patients with anterior circulation ischemic stroke who were admitted to the Department of Neurology of the First Hospital of Jilin University within 48 hours of symptom onset and were aged 18-80 years

Exclusion Criteria:

  • (1) patients who received intravenous thrombolysis or endovascular intervention; (2) patients with infectious diseases, autoimmune diseases, or those receiving immunosuppressive or immunomodulatory therapy; (3) patients with a history of cerebral infarction or intracerebral hemorrhage within the past year; (4) patients with severe hepatic or renal dysfunction, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding three times the upper limit of normal, serum creatinine levels >265 μmol/L, heart failure, or malignant tumors.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
mild stroke
admission NIHSS score ≤ 6
moderate-to-severe stroke
admission NIHSS score > 6
control
Volunteers from the health examination center were recruited as controls

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
3-month mRS
Time Frame: three months after the onset of the disease
Functional outcomes were assessed at 3 months by trained medical personnel via telephone interviews using the modified Rankin Scale (mRS). Favorable outcomes were defined as no symptoms to mild disability (mRS 0-2), whereas unfavorable outcomes were defined as moderate disability to death (mRS 3-6).
three months after the onset of the disease

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The First Hospital of Jilin University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 6, 2023

Primary Completion (Actual)

June 3, 2024

Study Completion (Actual)

September 1, 2024

Study Registration Dates

First Submitted

March 31, 2026

First Submitted That Met QC Criteria

March 31, 2026

First Posted (Actual)

April 7, 2026

Study Record Updates

Last Update Posted (Actual)

April 7, 2026

Last Update Submitted That Met QC Criteria

March 31, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 23K099-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The paper has not yet been published and is therefore not available for public disclosure at present.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Cerebral Infarction

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe